TNFRSF1B and familial pancreatic carcinoma: Meanwhile, anti-TNFR2 and PD-L1 antibody combination therapy inhibits tumor growth, reduces Treg and tumor-associated macrophage infiltration, and induces the activation of CD8+ T cells in the pancreatic cancer microenvironment (94).